5-Aza-2′-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis

Cancer Investigation

Volumn 26, Issue 7, 2008, Pages 680-688

  Yagi, Shutaro ^a   Oda Sato, Eri ^a   Uehara, Ikuno ^a   Asano, Yumi ^a   Nakajima, Wataru ^a   Takeshita, Toshiyuki ^a   Tanaka, Nobuyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

5 Aza 2 deoxycytidine; Apoptosis; Noxa; p53; p53AIP1; PUMA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN HCT116; DRUG MECHANISM; EPIGENETICS; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CELL CYCLE; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 48249124220     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701840212     Document Type: Article

References (42)

1. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408(6810), 307-310.
2. Oren, M. Decision making by p53: life, death and cancer. Cell Death Differ 2003, 10(4), 431-442.
3. Lowe, S. W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature 2004, 432(7015), 307-315.
4. Green, D.R.; Evan, G.I. A matter of life and death. Cancer Cell 2002, 1(1), 19-30.
5. Bartkova, J.; Horejsi, Z.; Koed, K.; et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434(7035), 864-870.
6. Gorgoulis, V.G.; Vassiliou, L.V.; Karakaidos, P.; et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434 (7035), 907-913.
7. Oda, E.; Ohki, R.; Murasawa, H.; et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288(5468), 1053-1058.
8. Yu, J.; Zhang, L.; Hwang, P. M.; et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7(3), 673-682.
9. Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001, 7(3), 683-694.
10. Oda, K.; Arakawa, H.; Tanaka, T.; et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102(6), 849-862.
11. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100(1), 57-70.
12. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6), 415-428.
13. Feinberg, A.P.; Tycko, B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4(2), 143-153.
14. Baylin, S.B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005, 2 Suppl 1, S4-11.
15. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16(1), 6-21.
16. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1(4), 287-299.
17. Egger, G.; Liang, G.; Aparicio, A.; et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429(6990), 457-463.
18. Lyko, F.; Brown, R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005, 97(20), 1498-1506.
19. Soussi, T.; Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1(3), 233-240.
20. Chim, C.S.; Wong, A.S.; Kwong, Y.L. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. Am J Hematol 2005, 80(4), 282-287.
21. Lodygin, D.; Diebold, J.; Hermeking, H. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 2004, 23(56), 9034-9041.
22. Oshiro, M.M.; Futscher, B.W.; Lisberg, A.; et al. Epigenetic regulation of the cell type-specific gene 14-3-3sigma. Neoplasia 2005, 7(9), 799-808.
23. Polyak, K.; Waldman, T.; He, T.C.; et al. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996, 10(15), 1945-1952.
24. Noda, A.; Ning, Y.; Venable, S.F.; et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994, 211(1), 90-98.
25. Sato, M.; Suemori, H.; Hata, N.; et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13(4), 539-548.
26. Hida, S.; Ogasawara, K.; Sato, K.; et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000, 13(5), 643-655.
27. Whang, Y.E.; Wu, X.; Suzuki, H.; et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998, 95(9), 5246-5250.
28. Ishida, S.; Yamashita, T.; Nakaya, U.; et al. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 2000, 91(2), 174-180.
29. Yamano, S.; Tokino, T.; Yasuda, M.; et al. Induction of transformation and p53-dependent apoptosis by adenovirus type 5 E4orf6/7 cDNA. J Virol 1999, 73(12), 10095-10103.
30. Watson, J.V.; Chambers, S.H.; Smith, P.J. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 1987, 8(1), 1-8.
31. Sgonc, R.; Gruber, J. Apoptosis detection: an overview. Exp Gerontol 1998, 33(6), 525-533.
32. Danial, N.N.; Korsmeyer, S.J. Cell death: critical control points. Cell 2004, 116(2), 205-219.
33. Shibue, T.; Takeda, K.; Oda, E.; et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003, 17(18), 2233-2238.
34. Villunger, A.; Michalak, E.M.; Coultas, L.; et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003, 302(5647), 1036-1038.
35. Jeffers, J.R.; Parganas, E.; Lee, Y.; et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4(4), 321-328.
36. Miyashita, T.; Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80(2), 293-299.
37. Polyak, K.; Xia, Y.; Zweier, J.L.; et al. A model for p53-induced apoptosis. Nature 1997, 389(6648), 300-305.
38. Huang, J.; Perez-Burgos, L.; Placek, B.J.; et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444(7119), 629-632.
39. Le Cam, L.; Linares, L. K.; Paul, C.; et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006, 127(4), 775-788.
40. Nakajima, W.; Tanaka, N. Synergistic induction of apoptosis by p53-inducible Bcl-2 family proteins Noxa and Puma. J Nippon Med Sch 2007, 74(2), 148-157.
41. McCurrach, M.E.; Connor, T.M.; Knudson, C.M.; et al. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997, 94(6), 2345-2349.
42. Matzke, M.; Aufsatz, W.; Kanno, T.; et al. Genetic analysis of RNA-mediated transcriptional gene silencing. Biochim Biophys Acta 2004, 1677(1-3), 129-141.